Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office										Atty. Docket No. A31909-PCT-USA (072874.0153) Serial No. 09/848,948				Page 1 o		
( i i	INF			BY.	APPI	LICA	NT		EMENT	Applicants Hanash et al.						
(Use several sheets if necessary)										Filing Date May 4, 2001			Group Art Unit 1642			
	ى.								<del></del>	<del></del> -	<del></del>			<del></del> -		
Xam.	ARK	Ť		Docu	ment l					ENT DOCUMENT	<u>rs</u>	<del></del>	Т	<del></del>		
Init.	ļ	-	Document No.					T =	Date	Name		Class	Subclass	Filing Date		
50	<u> </u>	5	4	0	5	7	4	9	04/11/95	Polans et al.						
<u>.</u>	_	5	3	5	0	6	8	7	09/27/94	Odink et al.		750	EIVE	<b>)</b>		
	ļ	<del> </del>	-			-	╂	-	<del> </del>			OCT 1	7 2003			
		├	<del> </del>	├-	├-	-	╄	<del> </del>	ļ		J					
			<del> </del>	<u> </u>	<u> </u>	ļ	-	ļ		•	IEUH	CENTE	R 1600/29	00		
		L		<u></u>	<u> </u>	<u></u>	<u> </u>	Ŀ	<u> </u>			_				
- Т		Ι –					··		FOREIGN PA	ATENT DOCUME	ENT			<u></u>		
	•		Document No.						Date	Country				Translate		
2		9	8	3	7	4	2	0	08/27/98	WO		Class	SubClass	Yes No		
		9	8	3	5	9	8	5	08/20/98	wo			,			
		9	8	0	1	4	7	1	01/15/98	wo						
		2	0	4	5	7	5	9	10/10/95	RU			<del></del>			
P		0	5	8	5	2	0	1	03/02/94	EP						
					ТНЕ	ER D	OCU	MEN'	TS (including	Author, Title Dat						
2			Mod	hizuk ironm	ı cı a.	1., (17	ソフリ	rosse	ssion System:	Middleware for Ad	e, Pertinent Page aptive Multiuser A	s, Etc.) pplicati	ons in a Mo	bile		
-			Karr	ell et hemic	al. (1 al ma	997) irkers	"S100	)B pro	otein, 5-S-cyste	einyldopa and 6-hyo patients with malig	droxy-%-methoxy	indole-2	-carboxylic	acid as		
	+		Hans		t al., (	(1997	) "Pro	gnost		rum Analyses of S-						
	+	7	E. vo Mela	n Sch noma	oultz Rese	et al.	, (199 vol. 6	6) "P 5: 133	rognostic value	e of serum analyses	of S-100B protein	in mali	gnant melan	oma",		
			Merz huma	ak et : in glic	al., (l oma c	994), ell lin	"Ove	rexpr vitro"	ession of the / , Neuropathol	8A2/mts1 gene and App. Neurobiol, 20	down-regulation of 614-619.	of the TI	MP-2 gene	in invasive		
uner									Date (	<u></u>						

Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

NY02:458672.1

Form PTO-1449 U.S. Department of Commerce (REV. 2-82) Patent and Trademark Office									Atty.	Page 2 of Serial No. 09/848,948						
INFORMATION DISCLOSURE STATEMENT BY APPLICANT										Applicants Hanash et al.						
(Use several sheets if necessary)									Filing May	Date 4, 2001	Group Art Unit 1642					
7 1 0 200																
					_			U.S. PAT	ENT DOC	UMENTS		,				
xam. Init.		Τ-	Docu	iment l	No.			Date		Name	Cla	ss Subclass		Filing Date		
	-	-	┿	┼	-		$\perp$									
		+	╁	+	-	-	-					H CENT	ECA	<u> </u>	_	
	╁-	+-	┼—	╁	+	-	┼		<del> </del>			00.		VE	5	
	+-	╁	┼	╀-	-	<del> </del>		<del> </del>	<u> </u>			7007	17	2002		
	-	<b>├</b>	<del> </del>	ļ	↓	↓_	<u> </u>				IEC	H CENT	70		_	
		<u></u>				<u></u>	<u> </u>				-		<del>41 18</del> 0	0/2000		
	Т		<u> </u>					FOREIGN PA	ATENT D	OCUMENT				<u> </u>		
	9	2	Docum	nent N		<del></del>	Т.	Date		Country	Clas	s SubC	Class	<u>Trans</u> Yes	ato	
2	<del> </del>		<u> </u>	L°	5	3	5	10/29/92	wo						<u>,,,</u>	
				<u> </u>						· · · · · · · · · · · · · · · · · · ·				- : . · ·		
	ļ															
											<del></del>				_	
	1								<del> </del>		<del></del>					
-				TUI		OCU	MEN	200 (:	. <u>.                                   </u>					l		
て		Path	ol An	al cell at 42	carci 2: 351	inoma 1-355.	of th	e wrinary blade	tein-positi	Fitle Date, Perting ve dendritic cells ion to turnour pro- and Applications ies and Antigens	and expression gression and p	of HLA- rognosis"	, Virch	ows Arc		
		Volle	er et a	il., (19	978) '	'Enzy	me in	nmunoassays v	vith specia	reference to ELI	SA techniques	", J. Clin.	Pathol	., 31: 50	7-	
,		520.														
,		520.									c				_	

<sup>\*</sup> Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not NY02:458672.1